Stevanato Group Spa
STVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.3B
Close$
$3.02
84.3% downside
Current Fair Value
84.3% downsideOvervalued by 84.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.30 Billion |
|---|---|
| Enterprise Value | $5.75 Billion |
| Dividend Yield | $0.06 (0.32%) |
| Earnings per Share | $0.49 |
| Beta | 0.78 |
| Outstanding Shares | 273,000,000 |
Return
| Return on Equity | 8.66% |
|---|---|
| Return on Assets | 5.13% |
| Return on Invested Capital | 9.76% |
Valuation & Multiples
| P/E Ratio | 36.07 |
|---|---|
| PEG | -159.88 |
| Price to Sales | 4.81 |
| Price to Book Ratio | 3.85 |
| Enterprise Value to Revenue | 4.71 |
| Enterprise Value to EBIT | 28.88 |
| Enterprise Value to Net Income | 42 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.35 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.14
Average shareholder expectationRevenue Estimate
$340.58 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.18
Average shareholder expectationRevenue Estimate
$363.58 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.33%▼ 16.07% |
|---|---|
| Total Invested | $18.66M▼ 97.69% |
| Investors Holding | 6▼ 121.00% |
ESG Score
No data
About Stevanato Group Spa
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end por...